ARKG News and Press, ARK Genomic Revolution ETF From 12/13/21

It's been a rough year for Cathie Wood's ARK Genomic Revolution ETF (NYSEMKT: ARKG) . The exchange-traded fund has fallen more than 30% so far in 2021. In this Motley Fool Live video recorded on Dec. 1 , Motley Fool contributors Keith Speights and Brian Orelli discuss w...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The tech underpinning Bionano Genomics (NASDAQ: BNGO ) stock is a cool genomics sequencing device called Saphyr . It claims to do genomic mapping faster, and better, than ever before possible. The machine costs $150...

It's not that difficult to spread your investments out across many companies and hope for the best over a long time horizon. After all, diversification limits the damage any one company can do to your portfolio. Force an investor to choose just one company and it's natural to look f...

Cathie Wood believes in the potential of gene editing. She stated last December that the "biggest upside surprises are going to come from the genomic space." It's not surprising that Wood's ARK Genomic Revolution ETF (NYSEMKT: ARKG) and ARK Innovation ETF (NYSEMKT: ARKK) ...

Stocks are driven by stories. Although long-term performance is determined by how much a company earns, its price at any given time is a reflection of the story market participants choose to believe. That's why markets have buyers and sellers. They believe different stories about the compan...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Crispr Therapeutics AG (NASDAQ: CRSP ) has the kind of DNA to become the next big thing in the market. But how does CRSP stock shape up as a purchase for today’s investors? Let’s take a look at what’...

Cathie Wood and her ARK Investment Management firm focus on areas of disruptive innovation. And few sectors have the potential to be more disruptive than genomics, where recent advancements are set to transform the healthcare industry. Technology improvements and cost reductions in genetic ...

In 2016, Cathie Wood and ARK investment management described Illumina (NASDAQ: ILMN) as "the cornerstone of our Genomic Revolution theme, and one of our highest conviction stocks." Illumina became one of the largest holdings across several ARK ETFs including the ARK Innovation ETF...

Over the past few years, Cathie Wood's ARK Invest group of exchange-traded funds have delivered impressive gains. ARK Invest's most successful fund over the past year, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) has the best performer of the bunch with an incredible 80% gain over...

Cathie Wood's ARK Genomic Revolution ETF (NYSEMKT: ARKG) focuses on investing in companies that could profit from using genomics to improve the quality of human life. The ETF currently owns positions in 60 individual stocks. In this Motley Fool Live video recorded on May ...